Search research articles
Contact Us
Filters
Showing results (161-170 of 277) with videos related to
Page
of 28
Sort By:
BMC Medical Informatics and Decision Making
|
February 18, 2021
User-centered and theory-based design of a professional training program on shared decision-making with older adults living with neurocognitive disorders: a mixed-methods study
Moulikatou Adouni Lawani, Yves Turgeon, Luc Côté, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics
S J DeNardo, G L DeNardo, D G DeNardo, et al.
Clinical Lymphoma
|
November 15, 2001
Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma
G L DeNardo, S J DeNardo, R T O'Donnell, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery
|
March 10, 2025
Comparing Bilateral and Single-Sided Deaf Cochlear Implant Recipients in a Novel Speech-in-Noise and Localization Task
Obada Abdulrazzak, Nadine I Ibrahim, Gerilyn Jones, et al.
Current Developments in Nutrition
|
May 14, 2023
Calcium Supplements and Risk of CVD: A Meta-Analysis of Randomized Trials
Xiqian Huo, Robert Clarke, Jim Halsey, et al.
Hybridoma
|
June 17, 1998
New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor
X Feng, R H Pak, L A Kroger, et al.
Blood
|
January 4, 2003
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts
Joseph M Tuscano, Robert T O'Donnell, Laird A Miers, et al.
International Journal of Particle Therapy
|
October 20, 2018
RBE Model-Based Biological Dose Optimization for Proton Radiobiology Studies
Fada Guan, Changran Geng, Duo Ma, et al.
Cancer
|
December 24, 1997
Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma
S J DeNardo, L A Kroger, K R Lamborn, et al.
Cancer Research
|
December 1, 1995
Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies
G L DeNardo, K R Lamborn, S J DeNardo, et al.
Page
of 28
Search research articles
Search
Showing results (161-170 of 277) with videos related to
Sort By:
Page
of 28
BMC Medical Informatics and Decision Making
|
February 18, 2021
User-centered and theory-based design of a professional training program on shared decision-making with older adults living with neurocognitive disorders: a mixed-methods study
Moulikatou Adouni Lawani, Yves Turgeon, Luc Côté, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics
S J DeNardo, G L DeNardo, D G DeNardo, et al.
Clinical Lymphoma
|
November 15, 2001
Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma
G L DeNardo, S J DeNardo, R T O'Donnell, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery
|
March 10, 2025
Comparing Bilateral and Single-Sided Deaf Cochlear Implant Recipients in a Novel Speech-in-Noise and Localization Task
Obada Abdulrazzak, Nadine I Ibrahim, Gerilyn Jones, et al.
Current Developments in Nutrition
|
May 14, 2023
Calcium Supplements and Risk of CVD: A Meta-Analysis of Randomized Trials
Xiqian Huo, Robert Clarke, Jim Halsey, et al.
Hybridoma
|
June 17, 1998
New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor
X Feng, R H Pak, L A Kroger, et al.
Blood
|
January 4, 2003
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts
Joseph M Tuscano, Robert T O'Donnell, Laird A Miers, et al.
International Journal of Particle Therapy
|
October 20, 2018
RBE Model-Based Biological Dose Optimization for Proton Radiobiology Studies
Fada Guan, Changran Geng, Duo Ma, et al.
Cancer
|
December 24, 1997
Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma
S J DeNardo, L A Kroger, K R Lamborn, et al.
Cancer Research
|
December 1, 1995
Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies
G L DeNardo, K R Lamborn, S J DeNardo, et al.
Page
of 28